Future Oncology
Papers 3306
1 page of 331 pages (3,306 results)
#1Felice Crocetto (University of Naples Federico II)H-Index: 1
#2B. Barone (University of Naples Federico II)
Last. Massimiliano Creta (University of Naples Federico II)H-Index: 9
view all 4 authors...
#1Maria Salvina Signorelli (University of Catania)H-Index: 13
#2Teresa Surace (University of Catania)H-Index: 1
Last. Eugenio Aguglia (University of Catania)H-Index: 29
view all 4 authors...
Cancer is a leading cause of death worldwide. Literature reports depression and anxiety are the most common psychiatric symptoms in cancer patients. Notably, lung cancer is associated with major depressive disorder in 5-13% of cases. The present article aims to give an overview regarding the impact of mood disorders on the outcomes of patients affected by lung cancer. Our review showed that pharmacological treatment and psychotherapy can be useful to improve the quality of life of patients with ...
#1Ezzeldin M. IbrahimH-Index: 22
#2Ahmed A. RefaeH-Index: 1
view all 4 authors...
Aim: Poly(ADP-ribose) polymerase inhibitors (PARPIs) improved progression-free survival among patients with recurrent ovarian cancer. This meta-analysis examined the effectiveness of PARPIs as maintenance strategy for newly diagnosed patients with advanced high-grade ovarian cancer with or without mutations. Materials & methods: Using defined selection criteria, a literature search identified four eligible randomized clinical trials involving 2386 patients. Results: Compared with placebo mainten...
#1Pau Montesinos (ISCIII: Carlos III Health Institute)H-Index: 13
#2Benjamin Beckermann (Hoffmann-La Roche)H-Index: 1
Last. Aaron Park (Hoffmann-La Roche)
view all 17 authors...
Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53. By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status. MIRROS (NCT02545283) is a randomized Phase III trial evaluating idasanutlin + cytarabine versus placebo + cytarabine in R/R AML. The primary ...
#1Shichao Zhou (SJTU: Shanghai Jiao Tong University)
#2Hai-Hua Yuan (SJTU: Shanghai Jiao Tong University)H-Index: 7
Last. Wen-Ying Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 5
view all 8 authors...
Aim: To explore the prognostic value of the systemic inflammatory marker (SIM) based on neutrophil, lymphocyte and monocyte counts in head and neck squamous cell carcinoma (HNSCC) patients. Patients & methods: We retrospectively collected the data of 367 patients with HNSCC who underwent surgery. The Kaplan-Meier survival analysis and Cox regression analysis were conducted on disease-free survival and overall survival. Results: A high SIM (>1.34) was associated with larger tumor size, advanced c...
#1Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 52
#2Neal D. ShoreH-Index: 36
Last. Gary K. SteinbergH-Index: 85
view all 10 authors...
Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guerin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patient...
#1S. Ponce AixH-Index: 2
#2Denis C. TalbotH-Index: 27
Last. Duncan J. StewartH-Index: 40
view all 16 authors...
#2Shaomin Wei (Tongji University)
Last. Li Gao
view all 7 authors...
Aim: Our aim was to analyze the clinicopathological features of lung, liver, bone and brain metastasis in patients with endometrial cancer (EC). Patients & methods: We screened patients diagnosed with EC between 2010 and 2015 from the Surveillance, Epidemiology and End Results database. Results: Among 69,027 eligible EC patients, lung metastasis was the most common. Patients with lung or liver metastasis were at higher risk of bone and brain metastases than those without lung and liver metastasi...
#1Fredrik Schjesvold (Oslo University Hospital)H-Index: 7
#2Pawel Robak (Medical University of Łódź)H-Index: 12
Last. Pieter Sonneveld (EUR: Erasmus University Rotterdam)H-Index: 88
view all 5 authors...
Melphalan flufenamide (formerly melflufen) is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melphalan flufenamide + dexamethasone versus pomalidomide + dexamethas...
#1Duoying Wang (WMU: Weifang Medical University)
#2Dong Guo (Union Hospital)
Last. J. M. Yu (Academy of Medical Sciences, United Kingdom)H-Index: 31
view all 6 authors...
Aim: To investigate the predictive potential of post-treatment neutrophil-to-lymphocyte ratio (NLR) and changes in this ratio (DeltaNLR) for stage III non-small-cell lung cancer (NSCLC) patients who received conventionally fractionated radiotherapy (CFRT). Patients & methods: The data of 168 NSCLC patients treated at the Shandong Cancer Hospital were analyzed retrospectively. The relationship between progression-free survival (PFS), overall survival (OS) and post-treatment NLR and DeltaNLR were ...
Top fields of study